Industry News

Alimera records $20.8 million net loss for first quarter

Alimera Sciences reported a GAAP net loss of $20.8 million, or $0.58 per common share, in the first quarter of 2014, compared with a net loss of $14 million, or $0.44 per common share, in the first quarter of 2013, according to a press release.

Non-GAAP net loss was $7.1 million, or $0.20 per common share, compared with a net loss of $8.4 million, or $0.27 per common share, in 2013.

Revenue in the first quarter was $2.1 million, an increase from $935,000 in the fourth quarter of 2013.

Research and development expenses increased to $2.6 million in the first quarter of 2014, compared with $2 million in the first quarter of 2013; general and administrative expenses increased to $2.9 million from $2.7 million; and sales and marketing expenses decreased to $3.4 million from $3.6 million.

Alimera Sciences reported a GAAP net loss of $20.8 million, or $0.58 per common share, in the first quarter of 2014, compared with a net loss of $14 million, or $0.44 per common share, in the first quarter of 2013, according to a press release.

Non-GAAP net loss was $7.1 million, or $0.20 per common share, compared with a net loss of $8.4 million, or $0.27 per common share, in 2013.

Revenue in the first quarter was $2.1 million, an increase from $935,000 in the fourth quarter of 2013.

Research and development expenses increased to $2.6 million in the first quarter of 2014, compared with $2 million in the first quarter of 2013; general and administrative expenses increased to $2.9 million from $2.7 million; and sales and marketing expenses decreased to $3.4 million from $3.6 million.